Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
FLT3 mutations in AML adversely associate with CR with intensive chemotherapy
August 6th, 2004
FLT3 mutations are adversely associated with complete remission in AML patients given intensive chemotherapy. "The prognostic impact of FLT3 mutations on the outcome of patients with diploid AML, treated with intensive chemotherapy, was analyzed," investigators in the United States report. "In 176 patients, the frequency of single ITD was 30% (<61 years: 37%, >60 years: 23%), single D835 mutation 2.3% and both 2.3%. There was no association between ITD and CR rate," said M. Beran and coworkers. "ITD-positive patients <61 years had a higher frequency of resistant disease. ITD was adversely associated with CR duration and...
Source: Genomics & Genetics Weekly (2004-08-06)
|
